Caris Life Sciences Study Identifies Clinically Significant Gene Fusions in Over 34,000 Tumors
- Caris Life Sciences on November 16, 2026, announced two studies already presented at the Association for Molecular Pathology’s 2026 annual meeting.
- Patients with novel ALK or FGFR2 fusions had survival comparable to those with established fusions when receiving matched tyrosine kinase inhibitors.
- Both groups survived longer than patients receiving treatments other than tyrosine kinase inhibitors.
- A separate study identified rare PAK-family gene fusions in gynecologic serous cancers, potentially informing future targeted-therapy research.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.